2. Trump officials' coronavirus drug dysfunction
A complete breakdown in communication and coordination within the Trump administration has undermined the distribution of a promising treatment, according to senior officials with direct knowledge of the discussions.
Why it matters: The drug, remdesivir, hasn't made it to some of the high-priority hospitals where it's most needed, and administration officials have responded by shifting blame and avoiding responsibility, sources told Axios' Jonathan Swan.
Where it stands: Gilead Sciences, the company that makes remdesivir, donated hundreds of thousands of doses to the federal government after the Food and Drug Administration authorized it as an emergency treatment for coronavirus patients.
- More than 32,000 doses of remdesivir were shipped and delivered on Tuesday to Indiana, Massachusetts, New Jersey, New York, Rhode Island, Tennessee and Virginia.
- But many of these doses went to "less impacted counties," an administration official said.
"Some went to the wrong places, some went to the right places," said one senior official. "We don't know who gave the order. And no one is claiming responsibility."
What they're saying: "An initial allocation of the drug remdesivir was made to seven states on Tuesday, and — after consultation with health experts — HHS will be managing distribution of the next tranche of the treatment to 16 states tonight and tomorrow, based on urgent need," Devin O'Malley, a spokesman for the White House Coronavirus Task Force, told Axios last night.
Read the scoop.